company background image
OFSA

Ouro Fino Saúde Animal ParticipaçõesBOVESPA:OFSA3 Stock Report

Market Cap

R$1.5b

7D

-2.5%

1Y

-5.2%

Updated

26 Oct, 2021

Data

Company Financials +
OFSA3 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance5/6
Financial Health5/6
Dividends0/6

OFSA3 Overview

Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, operates in the animal health industry primarily in Brazil.

Ouro Fino Saúde Animal Participações Competitors

Novartis

SWX:NOVN

CHF174.2b

Bayer

XTRA:BAYN

€47.9b

Elanco Animal Health

NYSE:ELAN

US$15.8b

Virbac

ENXTPA:VIRP

€3.5b

Price History & Performance

Summary of all time highs, changes and price drops for Ouro Fino Saúde Animal Participações
Historical stock prices
Current Share PriceR$27.30
52 Week HighR$26.40
52 Week LowR$42.00
Beta0.89
1 Month Change-7.52%
3 Month Change-19.71%
1 Year Change-5.21%
3 Year Change3.41%
5 Year Change-26.79%
Change since IPO-1.27%

Recent News & Updates

May 27
Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Has A Pretty Healthy Balance Sheet

Ouro Fino Saúde Animal Participações (BVMF:OFSA3) Has A Pretty Healthy Balance Sheet

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

OFSA3BR PharmaceuticalsBR Market
7D-2.5%-3.0%-3.6%
1Y-5.2%-4.8%0.7%

Return vs Industry: OFSA3 matched the BR Pharmaceuticals industry which returned -4.8% over the past year.

Return vs Market: OFSA3 underperformed the BR Market which returned 0.7% over the past year.

Price Volatility

Is OFSA3's price volatile compared to industry and market?
OFSA3 volatility
OFSA3 Beta0.89
Industry Beta0.61
Market Beta1

Stable Share Price: OFSA3 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: OFSA3's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/aKleber Cesar Gomeshttps://www.ourofinosaudeanimal.com

Ouro Fino Saúde Animal Participações S.A., together with its subsidiaries, operates in the animal health industry primarily in Brazil. The company operates through Production Animals, Companion Animals, and International Operations segments. It engages in the manufacture and sale of veterinary products, vaccines, and other products comprising anti-inflammatories, antibiotics, anticoccidials, anti-mastitis, ectoparasiticides, endectocides, endoparasiticides, hemoparasiticides, inoculants, therapeutics, and products for cattle, pigs, poultry, sheep, horses, and goats; and veterinary solutions, such as anesthetics, sedatives, anti-inflammatory, antibiotic, antimicrobial, dermatological, ectoparasiticide, endoparasiticide, dermocosmetic, and otological products for dogs and cats.

Ouro Fino Saúde Animal Participações Fundamentals Summary

How do Ouro Fino Saúde Animal Participações's earnings and revenue compare to its market cap?
OFSA3 fundamental statistics
Market CapR$1.51b
Earnings (TTM)R$118.62m
Revenue (TTM)R$845.46m

12.4x

P/E Ratio

1.7x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OFSA3 income statement (TTM)
RevenueR$845.46m
Cost of RevenueR$414.07m
Gross ProfitR$431.39m
ExpensesR$312.77m
EarningsR$118.62m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

Nov 11, 2021

Earnings per share (EPS)2.20
Gross Margin51.02%
Net Profit Margin14.03%
Debt/Equity Ratio56.2%

How did OFSA3 perform over the long term?

See historical performance and comparison

Valuation

Is Ouro Fino Saúde Animal Participações undervalued compared to its fair value and its price relative to the market?

12.42x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: OFSA3 (R$27.3) is trading above our estimate of fair value (R$18.94)

Significantly Below Fair Value: OFSA3 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: OFSA3 is good value based on its PE Ratio (12.4x) compared to the Global Pharmaceuticals industry average (23.1x).

PE vs Market: OFSA3 is poor value based on its PE Ratio (12.4x) compared to the BR market (11.5x).


Price to Earnings Growth Ratio

PEG Ratio: OFSA3's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: OFSA3's PB Ratio (2.4x) is in line with the XS Pharmaceuticals industry average.


Future Growth

How is Ouro Fino Saúde Animal Participações forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-0.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OFSA3's earnings are forecast to decline over the next 3 years (-0.3% per year).

Earnings vs Market: OFSA3's earnings are forecast to decline over the next 3 years (-0.3% per year).

High Growth Earnings: OFSA3's earnings are forecast to decline over the next 3 years.

Revenue vs Market: OFSA3's revenue (5.8% per year) is forecast to grow slower than the BR market (7.7% per year).

High Growth Revenue: OFSA3's revenue (5.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OFSA3's Return on Equity is forecast to be low in 3 years time (14.7%).


Past Performance

How has Ouro Fino Saúde Animal Participações performed over the past 5 years?

33.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OFSA3 has high quality earnings.

Growing Profit Margin: OFSA3's current net profit margins (14%) are higher than last year (7.9%).


Past Earnings Growth Analysis

Earnings Trend: OFSA3's earnings have grown significantly by 33.6% per year over the past 5 years.

Accelerating Growth: OFSA3's earnings growth over the past year (135.9%) exceeds its 5-year average (33.6% per year).

Earnings vs Industry: OFSA3 earnings growth over the past year (135.9%) exceeded the Pharmaceuticals industry 17.3%.


Return on Equity

High ROE: OFSA3's Return on Equity (19.7%) is considered low.


Financial Health

How is Ouro Fino Saúde Animal Participações's financial position?


Financial Position Analysis

Short Term Liabilities: OFSA3's short term assets (R$631.5M) exceed its short term liabilities (R$165.2M).

Long Term Liabilities: OFSA3's short term assets (R$631.5M) exceed its long term liabilities (R$294.8M).


Debt to Equity History and Analysis

Debt Level: OFSA3's debt to equity ratio (56.2%) is considered high.

Reducing Debt: OFSA3's debt to equity ratio has reduced from 62.1% to 56.2% over the past 5 years.

Debt Coverage: OFSA3's debt is well covered by operating cash flow (20.3%).

Interest Coverage: OFSA3's interest payments on its debt are well covered by EBIT (11.7x coverage).


Balance Sheet


Dividend

What is Ouro Fino Saúde Animal Participações's current dividend yield, its reliability and sustainability?

1.80%

Forecast Dividend Yield


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OFSA3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OFSA3's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OFSA3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OFSA3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: OFSA3 is not paying a notable dividend for the BR market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OFSA3's dividend in 3 years as they are not forecast to pay a notable one for the BR market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average board tenure


CEO

Kleber Cesar Gomes (46 yo)

1.5yrs

Tenure

Mr. Kleber Cesar Silveira Gomes serves as Chief Executive Officer at Ouro Fino Saúde Animal Participações S.A since April 1, 2020 and serves as its Member of Executive Board. Mr. Gomes served as Chief Inve...


Board Members

Experienced Board: OFSA3's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Ouro Fino Saúde Animal Participações S.A.'s employee growth, exchange listings and data sources


Key Information

  • Name: Ouro Fino Saúde Animal Participações S.A.
  • Ticker: OFSA3
  • Exchange: BOVESPA
  • Founded: 1987
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: R$1.511b
  • Shares outstanding: 53.95m
  • Website: https://www.ourofinosaudeanimal.com

Number of Employees


Location

  • Ouro Fino Saúde Animal Participações S.A.
  • Rodovia Anhanguera SP 330
  • Km 298
  • Cravinhos
  • São Paulo
  • 14140-000
  • Brazil

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/26 22:57
End of Day Share Price2021/10/26 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.